Skip to main content
Evidence-Based Supplement Research
Evidence-Based Supplement Research
Pillser
Search
Sign UpLog In

Lactobacillus brevis SBC8803

What does the research say about Lactobacillus brevis SBC8803?

12 health outcomes synthesised

Research on Lactobacillus brevis SBC8803 spans 12 health outcomes, with the strongest evidence for skin hydration, sleep quality, and intestinal barrier function. The most studied area is skin hydration (10 papers, the majority of which are reviews citing a single primary RCT), though evidence strength is rated low due to publication bias and marginal statistical significance. Doses in the primary RCT ranged from 25–50 mg/day of heat-killed bacteria, studied in adults with mildly impaired skin barrier function.

Strongest evidence. No outcomes reached high or moderate evidence strength; all 12 syntheses are rated low or very low. The largest evidence base (10 papers) is for Improved Skin Hydration, where 10 of 10 studies reported beneficial effects, but only one meta-analysis reached statistical significance. The primary RCT used 25–50 mg/day of heat-killed SBC8803 in adults with elevated transepidermal water loss. Improved Sleep Quality (7 studies) and Improved Intestinal Barrier Function (5 studies) also show consistently positive directions but are limited by small sample sizes, reliance on reviews, and lack of statistical significance in most individual studies.

Mixed or weaker evidence. Outcomes with very low evidence strength include Improved Skin Health (6 studies), Reduced Inflammation (5 studies), Improved Liver Function (3 studies), and Improved Immune Function (3 studies). All studies in these categories reported beneficial effects, but none reported statistically significant findings, and the evidence comes predominantly from narrative reviews or animal/cell models. For inflammation, one small RCT in healthy adults found a moderate statistically significant effect on exercise-induced inflammation. For liver function, two of three studies are reviews and one is an animal model — no human clinical trial directly tests this outcome.

Effective dose patterns. Only one outcome, Improved Skin Hydration, had an extractable dose range: 25–50 mg/day of heat-killed SBC8803. No other syntheses reported consistent effective doses; dose, form, and duration data were often absent or unreported across studies.

Population insights. Most studied populations were generally healthy adults, including middle-aged women (skin hydration), healthy adults with high stress (sleep quality), and obese individuals without comorbidities (body fat reduction). No single population group consistently appeared across multiple outcomes sufficient to draw strong cross-cutting conclusions.

Notable caveats. Publication bias is flagged across all syntheses — null-result studies are less likely to be published or indexed. Many individual studies (and most reviews) did not reach statistical significance, suggesting true effect sizes may be smaller than the consistent positive direction implies. The evidence base for every outcome is small (3–10 studies) and heavily reliant on narrative reviews, with very few direct randomized controlled trials on the specific strain SBC8803. For several outcomes, the only human trial is a single pilot study with 17 participants (sleep quality). No outcome has high or moderate evidence strength; all are low or very low.

Frequently asked

  • What is Lactobacillus brevis SBC8803 good for according to research?
    Research suggests potential benefits for skin hydration (10 studies, all positive but mostly non-significant), sleep quality (7 studies, including one pilot crossover trial with 17 males showing significant improvement in waking), and intestinal barrier function (5 studies, all positive but none statistically significant). Effects have also been reported for reducing body fat, fatigue, inflammation, and liver injury, but the evidence is preliminary and mostly from reviews or animal models.
  • What dose of Lactobacillus brevis SBC8803 is typically used in studies?
    A specific effective dose has been clearly reported only for skin hydration, where one RCT used 25 mg/day and 50 mg/day of heat-killed SBC8803. For all other outcomes (sleep quality, body fat, fatigue, etc.), dose, form, and duration data were either not reported or inconsistent across studies, so no generalizable dose can be stated from the available evidence.
  • Who benefits most from Lactobacillus brevis SBC8803?
    The most studied populations are generally healthy adults. For skin hydration, studies focused on adults with slightly elevated transepidermal water loss and healthy middle-aged women. For sleep quality, the only direct trial enrolled healthy men (ages 41–69) with slightly high insomnia scores. For body fat reduction, one meta-analysis studied obese individuals without comorbidities. No single population consistently shows stronger benefits across multiple outcomes.
  • Are there caveats or limitations in the research on Lactobacillus brevis SBC8803?
    Yes. Publication bias is a concern across all 12 outcomes — studies with null results are less likely to be published. Most individual studies did not reach statistical significance, so the true effect may be smaller than the consistent positive direction suggests. The evidence base is small (3–10 studies per outcome) and heavily relies on narrative reviews rather than independent, large-scale randomized controlled trials. Many outcomes lack human clinical trials entirely and are supported only by animal or cell models.
  • Does Lactobacillus brevis SBC8803 help with sleep quality?
    Seven studies report beneficial effects on sleep quality, with moderate effect sizes. The most direct evidence comes from a small pilot crossover trial (17 males with slightly high Athens Insomnia Scale scores) that found significant improvement in waking and marginal improvement in daytime drowsiness. Three of the seven studies reached statistical significance. However, the evidence strength is rated low due to the small sample, publication bias concerns, and reliance on reviews.
  • Does Lactobacillus brevis SBC8803 help with reducing body fat?
    Four studies report beneficial effects, including one 2025 meta-analysis (n=58) that found a statistically significant small reduction in overall body fat (MD: -1.11; 95%CI: -1.31 to -0.91; p<0.00001) in obese individuals without comorbidities. The remaining three studies were narrative reviews without effect size detail. The evidence base is small and preliminary, and no consistent dose or duration data are available.

  • Simple Slumbers

    By Unisom

    Out of Stock
    Available From
    Available From
    MerchantPriceStockAction
    Amazon
    $-
    		Out
    iHerb
    $14.86
    		In
    Vitacost
    $-
    		Out
    Vitamin Shoppe
    $-
    		Out
Back to top